Pelthos Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $71.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $15.60M | $-6.62 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $10.91M | $-3.09 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | Before market open | $9.39M | $-6.87 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 18, 2025 | Before market open | – | – | – |
Press releases
Announcements Pelthos Therapeutics filed with the SEC
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
1 Corporate Presentation A U G U S T 2 0 2 6 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
1 Jefferies Global Healthcare Conference J U N E 4 , 2 0 2 6 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
1 Corporate Presentation M A Y 2 0 2 6 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Regulation FD disclosure · EX-99.1 to Form 8-K
1 Corporate Presentation A P R I L 2 0 2 6 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Pelthos Therapeutics Announces CFO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”)
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
Executive or director change · Other events · EX-99.1 to Form 8-K
Quarter Fiscal 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1%
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Presentation Q 4 2 02 5 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Prepaid expenses and other current assets
Acquisition or disposition completed · Results of operations · EX-99.1 to Form 8-K/A
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Acquisition or disposition completed · Results of operations · EX-99.2 to Form 8-K/A
Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our”
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
Regulation FD disclosure · EX-99.2 to Form 8-K
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
on 2024 Annual Report to Comply with NYSE American Listing Rules
Regulation FD disclosure · EX-99.1 to Form 8-K
Pelthos Therapeuties Corporate Corporate Presentation Presentation Q 2 2 0 2 5 SO) NSD) NaN CONFIDENTIAL 1
Material agreement · Unregistered share sale · Auditor change · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Material agreement · Unregistered share sale · Auditor change · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces Name Change to “Channel Therapeutics Corporation”
Regulation FD disclosure · EX-99.1 to Form 8-K
N.J., October 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”),
Shareholder vote results · Other events · EX-99.1 to Form 8-K
N.J., August 7, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”),
Other events · EX-99.1 to Form 8-K
CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non-Opioid Pain Treatment Therapies
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Issues Letter to Stockholders from Chief Executive Officer
Other events · EX-99.1 to Form 8-K
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
Regulation FD disclosure · EX-99.1 to Form 8-K
Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
Executive or director change · Other events · EX-99.1 to Form 8-K
CHROMOCELL THERAPEUTICS CORPORATION 1 CHROMOCELL THERAPEUTICS CORPORATION Potential Breakthrough Drug for Non - Opioid Pain Treatment Therapies
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Public Offering for Gross Proceeds of $6.6 Million
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K